Objective: To evaluate clinically the efficacy and safety in northern India of cefepime monotherapy versus piperacillin-tazobactam in patients of paediatric age group with febrile neutropenia.

Material And Methods: Children aged ≤18 years admitted febrile with chemotherapy-induced neutropenia were randomised into two groups comprising 20 cases in each group viz. CEF (receiving cefepime only) and PIP-TAZO (receiving piperacillin-tazobactam). Based on clinical and laboratory tests, patients were classified into: microbiologically documented infections (MDI); clinically documented infections (CDI); and unexplained fever (UF). They were assessed for clinical signs and symptoms as well as laboratory parameters at the time of enrolment and subsequently on days 3 and 7.

Results: Incidence of MDI, CDI and UF were 22.5%, 47.5% and 30%, respectively. The mean duration of neutropenia (in days) was 5.45 ± 2.1 in the PIP-TAZO group and 5.5 ± 1.5 in the CEF group (P = 0.305). The success rate defined as clearing infection effectively and improvement of neutropenia was comparable (P = 0.705). There was a mortality rate of 20% in the PIP-TAZO group as compared to 10% in the CEF group.

Conclusion: We conclude that cefepime monotherapy and piperacillin-tazobactam are equally efficacious and safe in treating patients with febrile neutropenia. Empirical monotherapy with cefepime would prevent an unnecessary extra economic burden as well as avoiding the serious adverse or toxic effects of multi-drug regimes, especially in low- and middle-income countries.

Download full-text PDF

Source
http://dx.doi.org/10.1177/0049475515617571DOI Listing

Publication Analysis

Top Keywords

cefepime monotherapy
12
efficacy safety
8
monotherapy versus
8
versus piperacillin-tazobactam
8
piperacillin-tazobactam patients
8
patients paediatric
8
paediatric age
8
age group
8
group febrile
8
febrile neutropenia
8

Similar Publications

Article Synopsis
  • Cefepime/enmetazobactam is a new antibiotic duo effective against multidrug-resistant Enterobacterales, particularly strains producing OXA-48 enzymes, with potential use in treating hospital-acquired pneumonia.
  • In a mouse study, combining cefepime with enmetazobactam significantly reduced bacterial levels in the lungs compared to treatment with either drug alone or with meropenem, especially against high-resistance strains.
  • These findings suggest cefepime/enmetazobactam could be a promising alternative for tackling lung infections caused by resistant Enterobacterales, demonstrating better antibacterial activity than currently used treatments.
View Article and Find Full Text PDF

Synergistic potential of Leu-teixobactin and cefepime against multidrug-resistant Staphylococcus aureus.

BMC Microbiol

October 2024

Department of Biochemistry and Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, 3010, Australia.

Staphylococcus aureus (S. aureus) is a significant Gram-positive opportunistic pathogen behind many debilitating infections. β-lactam antibiotics are conventionally prescribed for treating S.

View Article and Find Full Text PDF

Bacterial biofilms, often forming on medical devices, can lead to treatment failure due to their increased antimicrobial resistance. Cefepime-avibactam (CFP-AVI) exhibits potent activities against Pseudomonas aeruginosa (P. aeruginosa) and Klebsiella pneumoniae (K.

View Article and Find Full Text PDF

Objectives: Viridans streptococci (VS) are opportunistic oral commensals and a common cause of bacteraemia in neutropenic patients. In this retrospective single centre cohort study, we investigated the prevalence of ceftriaxone resistance in VS (CRO-R VS) blood isolates between January 2005 and December 2022 from patients treated at a tertiary care hospital.

Methods: Blood culture isolates were identified using biochemicals and mass spectrometry.

View Article and Find Full Text PDF

Objectives: To investigate clinical outcomes of patients with Pseudomonas endocarditis and identify factors associated with treatment failure.

Methods: Adult patients meeting definitive Duke's criteria for Pseudomonas endocarditis at 11 hospitals were identified between May 2000 and February 2024. Failure was defined as death or microbiological failure by day 42.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!